AviGen

Alameda, United States Founded: 1992 • Age: 34 yrs Acquired By MediciNova
Gene therapy products are developed for inherited and acquired diseases.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About AviGen

AviGen is a company based in Alameda (United States) founded in 1992 was acquired by MediciNova in February 2009. AviGen operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Serum Institute of India, among others.

  • Headquarter Alameda, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    MediciNova

    (Feb 09, 2009)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of AviGen

Premium access

Detailed funding history for AviGen

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in AviGen

AviGen has secured backing from 1 investor. Prominent investors backing the company include MediciNova.

All
Investor Description Founded Year Domain Location
Small-molecule therapeutics are developed for asthma, COPD, and neurologic diseases.
Locked Locked Locked
Premium access

Investor details for AviGen

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by AviGen

Investments
Premium access

Investment portfolio details for AviGen

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - AviGen

Premium access

Detailed financials for AviGen

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Avigen Comparisons

AviGen Primary company
Description
Gene therapy products are developed for inherited and acquir...
Location
Alameda, United States
Founded Year
1992
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for AviGen

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of AviGen

AviGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Serum Institute of India, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
mRNA-based therapeutics for diseases including cancer and infections are developed.
Locked Locked Locked
Therapeutics for genetic diseases are developed through targeted interventions.
Locked Locked Locked
Gene therapies for rare diseases including retinal dystrophies are developed.
Locked Locked Locked
Therapeutics for cancer and rare diseases are developed.
Locked Locked Locked
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
Locked Locked Locked
Vaccines for infectious diseases are developed using cell-free protein synthesis.
Premium access

Detailed competitors of AviGen

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Avigen

Premium access

Complete news archive for AviGen

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about AviGen

AviGen was founded in 1992.

AviGen is headquartered in Alameda, United States. It is registered at Alameda, California, United States.

Founded in 1992 and based in Alameda, United States, operations are focused on biotechnology, specifically gene therapy for diseases such as cancer, anemia, hemophilia, hyperlipidemia, and metabolic storage disorders. Proprietary technologies including AAV vectors and the Targeted Vector Integration system are utilized to deliver genes. Treatments for blood cell-related conditions like sickle cell anemia, beta-thalassemia, and HIV infection are also advanced.

AviGen's top competitors include Moderna, Spark Therapeutics and BridgeBio.

AviGen has 1 investor. Key investors include MediciNova.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available